By Helena Smolak
Roche Holding said it will initiate a late-stage trial for its Alzheimer's drug candidate trontinemab later this year after its mid-stage study showed positive results.
The Swiss pharma giant said Thursday during a conference that its experimental treatment showed a reduction of amyloid plaques--protein clumps in the brain that contribute to the disease's progression--in patients with Alzheimer's disease.
In addition, its plasma diagnostics test Elecsys pTau181 demonstrated the ability to determine whether or not someone has amyloid pathology, one of the hallmarks of Alzheimer's disease.
"We are pleased with the progress across our Alzheimer's portfolio as we move ahead with a Phase III trontinemab program and continue to expand our diagnostic solutions," Levi Garraway, Roche's Chief Medical Officer said.
More than 55 million people worldwide are living with dementia, of which around 70% have Alzheimer's. Up to three-quarters of people experiencing symptoms of Alzheimer's remain undiagnosed, according to Roche.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 03, 2025 09:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。